Exacompta Clairefontaine Quote - ALEXA | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
Europe
EU
Exacompta Clairefontaine (ALEXA) Share Price

Exacompta Clairefontaine (ALEXA)

147.00

1.00

( 0.68% )

Updated: 21:33:48

Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Current Price

147.00

Bid

146.00

Offer

147.00

Volume

51

147.00 Day's Range 147.00

135.00 52 Week Range 178.00

Market Cap

Previous Close

146.00

Open

147.00

Last Trade

Last Trade Time

21:33:48

Financial Volume

-

VWAP

-

Average Volume (3m)

52

Shares Outstanding

1,131,480

Dividend Yield

4.56%

PE Ratio

3.60

Earnings Per Share (EPS)

38.11

Revenue

883.75M

Net Profit

43.12M

Sector

Pulp Mills

Industry

Paper And Allied Products

Website

www.exacomptaclairefontaine.fr

Headquarters

Saint-die-des-vosges, Vosges, Fra

Founded

1858

Exacompta Clairefontaine is listed in the Pulp Mills sector of the Euronext with ticker ALEXA. The last closing price for Exacompta Clairefontaine was 146.00 €. Over the last year, Exacompta Clairefontaine shares have traded in a share price range of 135.00 € to 178.00 €.

Exacompta Clairefontaine currently has 1,131,480 shares in issue. The market capitalisation of Exacompta Clairefontaine is 165.20 € million. Exacompta Clairefontaine has a price to earnings ratio (PE ratio) of 3.60.

No news to show yet.

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1	0.684931506849	146	149	146	19	148.10309278	DE
4	-8	-5.16129032258	155	160	146	30	152.31107206	DE
12	5	3.52112676056	142	160	135	52	143.70114147	DE
26	-14	-8.69565217391	161	170	135	55	146.09303008	DE
52	-16	-9.81595092025	163	178	135	54	153.89843631	DE
156	49	50	98	194	90.5	76	133.13067856	DE
260	56	61.5384615385	91	194	90.5	76	130.31849592	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BIOSBiosenic	0.0121 € (53.16%)	38.34M
MLSMLSmalto	0.0125 € (47.06%)	2.62k
CYADCelyad Oncology SA	0.88 € (25.18%)	178.75k
MLEFAEduformAction	0.48 € (18.81%)	5k
MEMSMemscap	4.90 € (18.36%)	59.18k
DMSBSDiagnostic Medical Systems	0.0005 € (-75.00%)	2.51k
CNVCnova NV	0.26 € (-67.50%)	3.23k
CLEXCumulex NV	0.54 € (-33.33%)	318
ATOAtos SE	0.0017 € (-22.73%)	3.05B
GNROGeNeuro SA	0.1435 € (-20.28%)	1.08M
ATOAtos SE	0.0017 € (-22.73%)	3.05B
BIOSBiosenic	0.0121 € (53.16%)	38.34M
PHARMPharming Group NV	0.889 € (6.85%)	22.26M
ALCYBCybergun	0.0001 € (0.00%)	16.96M
ALTDTonner Drones	0.0116 € (9.43%)	14.43M

LiveFromThe416

LiveFromThe416 37 seconds ago

Just click board of directors at the top. Are you a child? Figure it out on your own.

againstallodds

againstallodds 54 seconds ago

Murex copper: heavy environmental obstacles

With past pollution by copper contamination on Mt Washington and huge amount of $ spent for rehabilitation, any new mining project, like JarHead’s Murex copper, will be under intense scrutiny by environmentalists and governments.

gdog

gdog 1 minute ago

One of these days and it seems like its getting closer.

chilar4567

chilar4567 1 minute ago

OVERSOLD TO THE MAX!!!!

RIGATONI

RIGATONI 1 minute ago

Great stuff! ~Rig

Trooperstocks

Trooperstocks 1 minute ago

Thanks for that article Bud. SGTM is making head waves in the fight for the future of our planet.

DA88

DA88 2 minutes ago

I can't decide if I think this is good or bad, I guess the market will decide for me.. also, if this was planned, why would they let him do the interview yesterday?

If he didnt stay on as CTO there had to be some hostility to this separation.

Was it Lebby's inability t

Moneymaker77777

Moneymaker77777 2 minutes ago

1vman

1vman 2 minutes ago

***** NO SIR !!! 🚽UBQU🚽 Does not have 5 million in revenues , point in fact financials are not very good and can be found here

https://www.otcmarkets.com/stock/UBQU/disclosure

ENOUGH SAID 🤪 !!!

Trooperstocks

Trooperstocks 3 minutes ago

That's correct. $SGTM is making things better for areas that are affected by lower precipitation levels and droughts!

underpar71

underpar71 3 minutes ago

Since we never get news, our only hope is a technical move. If we get some volume and get over the 100DMA at .32, that would be a boost. If we get over .34, should move to next resistance at .40. Would like to see over 5 million shares traded today and I think we can get over the 100DMA.
htt

golfbag

golfbag 3 minutes ago

I agree with you, X, 1,000%. Yves can get us across the goal line. I saw this same thing happen in another one of companies the new guy got the work done and increased shareholder value 8x.

Rais

Rais 3 minutes ago

Chartmaster

Chartmaster 4 minutes ago

CBD Life Sciences Inc. (CBDL) Looking to Acquire a Cannabis Growth License in North Las VegasPress Release | 12/11/2024

Target Acquisition Valued at $10 Million with Projected 2025 Gross Revenue of $5 Million, Positioning CBDL for Explosive Growth in Nevada's Burgeoning Cannabis Marke

Charlye

Charlye 4 minutes ago

And personally...what do you think about spirit?...will they succeed?

yp_1

yp_1 4 minutes ago

Wow, I am sure he notified you ahead of time so you would have your bid ready…

Chartmaster

Chartmaster 4 minutes ago

CBD Life Sciences Inc. (CBDL) Looking to Acquire a Cannabis Growth License in North Las VegasPress Release | 12/11/2024

Target Acquisition Valued at $10 Million with Projected 2025 Gross Revenue of $5 Million, Positioning CBDL for Explosive Growth in Nevada's Burgeoning Cannabis Marke

budfoxfun

budfoxfun 4 minutes ago

Introducing our innovative line of biological solutions for odor and waste management:

1. Bio-Seed: A probiotic inoculant that neutralizes odors, metabolizes odor-causing substances, and prevents the formation of hydrogen sulfide and other odor species. It includes tar

The_Truth_NL

The_Truth_NL 4 minutes ago

That's a ridiculous statement, but I've heard it hear several times during the last 3-4 years.
If it's too expensive- then why was the short volume over a billion shares 4 times last week? I haven't looked at this week, but it's easy enough for someone as sophisticated as you to look at.

axelvento

axelvento 5 minutes ago

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year

TrendTrade2016

TrendTrade2016 5 minutes ago

bucks2pennies

bucks2pennies 5 minutes ago

Quite informative can. Still, just more fertilized soil on an already existing can of worms. However, I am of the OPINION that the fact that the can of worms continues to grow tells me that there is still some interest in having GTCH gaining some footing in the business world.

A

sirant

sirant 5 minutes ago

GOOD MORNING EVERYONE

GO $MCIC

gp22

gp22 5 minutes ago

Quantum Pure Play: $WKEY Float 3.2M w/425K volume in pre market...: $LAES Float 16M w/ 61M volume in pre-market..$WKEY is the 100% owner of subsidiary Quantum company $LAES...Not one post on $LAES boards concerning this issue.

Exacompta Clairefontaine

Isramco Negev 2 Ltd Part... (CE)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions